Get the Stockscreener App
254.31
0.38%
0.96
After Hours:
254.00
-0.31
-0.12%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $254.31, with a volume of 9.36M.
It is up +0.38% in the last 24 hours and up +16.81% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$253.35
Open:
$253.05
24h Volume:
9.36M
Relative Volume:
1.36
Market Cap:
$449.31B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
125.44
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+10.56%
1M Performance:
+16.81%
6M Performance:
+10.17%
1Y Performance:
+39.49%
1-Day Range:
$249.20
$255.99
1-Week Range:
$231.30
$255.99
52-Week Range:
$181.75
$255.99
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
254.31 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,229.93 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
258.51 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
129.38 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.59 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Is AbbVie (ABBV) One of the 10 Best July Dividend Stocks to Buy? - Insider Monkey
AbbVie lymphoma trial cuts progression risk 60% in Phase 3 test - Stock Titan
AbbVie Stock Rockets 17% With 5-Day Winning Streak - Yahoo Finance
AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check - Yahoo Finance Singapore
What's Going On With AbbVie Stock Monday?AbbVie (NYSE:ABBV) - Benzinga
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy? - Yahoo Finance
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy? - The Motley Fool
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last? - Yahoo Finance
$100M AbbVie payment backs REGENXBIO (RGNX) Phase IIb/III eye gene therapy - Stock Titan
ABBV Gains Traction as CHMP Recommends Upadacitinib for Alopecia Areata - GuruFocus
AbbVie Stock Surges 17%, With A 5-Day Winning Spree - Trefis
AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Investing News Network
AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Non-segmental Vitiligo - Investing News Network
AbbVie gets positive EU opinion for vitiligo treatment By Investing.com - Investing.com Canada
AbbVie’s upadacitinib receives positive EU opinion for alopecia By Investing.com - Investing.com Canada
AbbVie Inc.(NYSE: ABBV) added to Russell 1000 Value Benchmark - marketscreener.com
AbbVie moves RINVOQ toward EU approval in severe alopecia areata - Stock Titan
AbbVie’s RINVOQ moves closer to Europe’s first vitiligo pill - Stock Titan
AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost - TechStock²
Skyrizi Just Hit $4.5 Billion in a Single Quarter, AbbVie’s Humira Problem Is Solved - TIKR.com
AbbVie (ABBV) Wins Health Canada Approval for Boey - Insider Monkey
AbbVie (NYSE:ABBV) jumps $18 billion Friday, beats Apogee as Skyrizi FDA decision comes Monday - TechStock²
AbbVie (ABBV) to Acquire Apogee Therapeutics - Insider Monkey
SCHULHOFF & CO INC's AbbVie Inc(ABBV) Holding History - GuruFocus
Enterprise value to revenue forward of AbbVie, Inc. CDR (CAD Hedged) – TSX:ABBV - TradingView
Key facts: AbbVie Q2 Jul 31; FDA Approves Skyrizi for 6+ & Ped PsA - TradingView
AbbVie (ABBV) Gains FDA Approval for Skyrizi in Children with Ps - GuruFocus
ABBV Gains FDA Approval for Skyrizi in Pediatric Psoriasis Treat - GuruFocus
AbbVie Inc (ABBV) Stock Up 4.2% but GF Value Says Overvalued -- GF Score: 82/100 - GuruFocus
AbbVie receives FDA approval for Skyrizi in pediatric patients By Investing.com - Investing.com Canada
AbbVie Inc Stock (ABBV) Closed Up by 3.53% on Jun 26: Facts Behind the Movement - TradingKey
Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Bill - Benzinga
Lilly, J&J and AbbVie Hit New Highs - TradingView
why dominant pharmaceutical firms are paying billion dollar premiums for immunology assets - grafa.com
Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms - Seeking Alpha
AbbVie Stock’s Growth Story Has One Question Mark - Trefis
AbbVie On Pace For Record Closing High -- Data Talk - Moomoo
AbbVie stock hits all-time high at 245.26 USD By Investing.com - Investing.com Nigeria
Price to book forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie stock hits all-time high at 245.26 USD - Investing.com
Price to earnings forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie to Host Second-Quarter 2026 Earnings Conference Call - Investing News Network
ABBV Stock Quote Price and Forecast - CNN
Rx Rundown: Merck KGaA, AbbVie, Sangamo Therapeutics and more - Medical Marketing and Media
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $275 - Moomoo
AbbVie, Inc. CDR (CAD Hedged) Actuals & Estimates (FWB:4AB0) - TradingView
AbbVie, Inc. Actuals & Estimates (VIE:ABBV) - TradingView
AbbVie, Inc. CDR (CAD Hedged) Actuals & Estimates (DUS:4AB0) - TradingView
Will AbbVie's (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix? - Yahoo Finance
Enterprise value to EBITDA forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? - The Motley Fool
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):